Thrombosis in vasculitis
- 1 January 2013
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 25 (1), 19-25
- https://doi.org/10.1097/bor.0b013e32835ad3ca
Abstract
To review the association of thrombosis and vasculitis and discuss some of the proposed causal mechanisms. It is becoming increasingly evident that various systemic inflammatory diseases such as vasculitis are associated with an increased risk of both venous and arterial thrombosis. Increasing evidence supports the use of immunosuppression in the management of venous thrombosis in Behçet's disease. An increased incidence of thromboembolic disease in antineutrophil cytoplasmic antibody-associated vasculitis has been recognized, especially during periods of active disease. In addition, a higher risk of ischemic heart disease in these patients has also been observed. As in giant cell arteritis, recent evidence supports the role of aspirin in the prevention of ischemic events in Takayasu's disease. Thromboembolic disease is an important complication of several forms of systemic vasculitis, and it may result in significant morbidity and mortality. Many questions such as the role for screening of asymptomatic patients, prevention of thrombosis, and duration of anticoagulation in patients with vasculitis remain unanswered. Future studies exploring the mechanisms of thrombosis and its link to inflammation may provide insights in predicting patients at a higher risk for thrombosis and improve outcomes.Keywords
This publication has 41 references indexed in Scilit:
- Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from SwedenBMC Neurology, 2012
- Risk of Subsequent Coronary Heart Disease in Patients Hospitalized for Immune-Mediated Diseases: A Nationwide Follow-Up Study from SwedenPLOS ONE, 2012
- Inflammation and hemostasisBiochemia Medica, 2012
- Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from SwedenThe Lancet, 2011
- Evaluation of Soluble P-Selectin as a Marker for the Diagnosis of Deep Venous ThrombosisClinical and Applied Thrombosis/hemostasis, 2011
- Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage studyBMC Medicine, 2011
- Interleukin-6: A Potential Target for Post-Thrombotic SyndromeAnnals of Vascular Surgery, 2010
- Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulationThrombosis and Haemostasis, 2008
- Etanercept plus Standard Therapy for Wegener's GranulomatosisThe New England Journal of Medicine, 2005
- Thrombosis and pediatric Wegener's granulomatosis: Acquired and genetic risk factors for hypercoagulabilityArthritis Care & Research, 2003